Drugs / Cixutumumab
last change Oct 2019 re-read 2 minutes ago

Cixutumumab

also known as IMC-A12 · A12 · NSC 742460

Monoclonal antibody targets IGF1R

Developed for
Ewing sarcoma/peripheral primitive neuroectodermal tumor · non-small cell lung carcinoma · synovial sarcoma · cancer · osteosarcoma · prostate adenocarcinoma · rhabdomyosarcoma · adrenal cortex carcinoma
+71 more · adult hepatocellular carcinoma · childhood epithelioid sarcoma · childhood malignant neoplasm · leiomyosarcoma · malignant peripheral nerve sheath tumor · neoplasm · pediatric angiosarcoma · pediatric fibrosarcoma · pediatric liposarcoma · prostate cancer · adult epithelioid sarcoma · adult extraskeletal osteosarcoma · adult fibrosarcoma · adult liposarcoma · adult malignant hemangiopericytoma · adult malignant mesenchymoma · alveolar rhabdomyosarcoma · alveolar soft part sarcoma · brainstem neoplasm · breast cancer · carcinoma · childhood kidney neoplasm · childhood malignant hemangiopericytoma · childhood malignant mesenchymoma · childhood pleomorphic rhabdomyosarcoma · colon carcinoma · colorectal cancer · cutaneous neuroendocrine carcinoma · dermatofibrosarcoma protuberans · desmoplastic small round cell tumor · embryonal rhabdomyosarcoma · esophageal adenocarcinoma · esophageal squamous cell carcinoma · extraskeletal myxoid chondrosarcoma · gastrin-producing neuroendocrine tumor · gastroesophageal junction adenocarcinoma · glioma · gliosarcoma · glucagonoma · head and neck cancer · head and neck squamous cell carcinoma · hepatoblastoma · HER2 positive breast carcinoma · hormone-resistant prostate carcinoma · liposarcoma · lung adenocarcinoma · lung cancer · lung carcinoid tumor · lung large cell carcinoma · male breast carcinoma · malignant peritoneal mesothelioma · malignant pleural mesothelioma · medullary thyroid gland carcinoma · neuroblastoma · neuroendocrine neoplasm · pancreas disorder · pancreatic insulinoma · paraganglioma · pineal body neoplasm · PPoma · rectal cancer · retinoblastoma · rhabdomyosarcoma with mixed embryonal and alveolar features · small cell lung carcinoma · soft tissue sarcoma · somatostatinoma · thymic carcinoma · thymoma · undifferentiated high grade pleomorphic sarcoma of bone · hepatocellular carcinoma · uveal melanoma
Investigated by
National Cancer Institute (NCI) · Eli Lilly and Company · M.D. Anderson Cancer Center · Genentech, Inc. · Medidata Solutions · NSABP Foundation Inc
+3 more · Parexel · SWOG Cancer Research Network · University of Washington

Trials 43 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 111 trials
Phase 1 NCT01204476 Oct 2010 → Jul 2014 PPoma, cutaneous neuroendocrine carcinoma, gastrin-producing neuroendocrine tumor, glucagonoma +5 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01182883 Jul 2010 → Apr 2012 brainstem neoplasm, glioma, pineal body neoplasm National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 1 NCT01061749 Nov 2009 → Apr 2013 neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01007032 Nov 2009 → Dec 2012 neoplasm Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT01008566 Aug 2009 → May 2016 adult hepatocellular carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00880282 Apr 2009 → Oct 2012 childhood malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00720174 Jun 2008 → Jan 2013 adult epithelioid sarcoma, adult extraskeletal osteosarcoma, adult fibrosarcoma, adult liposarcoma +17 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00678769 May 2008 → Jun 2013 cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00609141 Jan 2008 → Sep 2009 Ewing sarcoma/peripheral primitive neuroectodermal tumor, childhood malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00785941 Apr 2006 → Oct 2007 cancer Eli Lilly and Company Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT01026623 Oct 2009 → Feb 2013 hormone-resistant prostate carcinoma, prostate adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00699491 Oct 2008 → Sep 2013 male breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00778167 Oct 2008 → May 2012 non-small cell lung carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00617708 Mar 2008 → Sep 2012 pancreas disorder National Cancer Institute (NCI) Completed No outcome recorded
Phase 228 trials
Phase 2 NCT01614795 Jun 2012 → Apr 2014 Ewing sarcoma/peripheral primitive neuroectodermal tumor, alveolar soft part sarcoma, childhood epithelioid sarcoma, gliosarcoma +7 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00957853 Oct 2011 → Aug 2018 head and neck squamous cell carcinoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT01413191 Aug 2011 → Mar 2013 iris melanoma, medium/large size posterior uveal melanoma, small size posterior uveal melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01263782 May 2011 → Aug 2017 lung cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT01232452 Apr 2011 → Jan 2013 non-small cell lung carcinoma Eli Lilly and Company Completed No outcome recorded
Phase 2 NCT01120236 Dec 2010 → Jun 2015 prostate adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01142388 Sep 2010 → Jul 2014 overdue esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 2 NCT01160458 Jun 2010 → Aug 2016 malignant peritoneal mesothelioma, malignant pleural mesothelioma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00955305 Mar 2010 → Jan 2016 lung adenocarcinoma, lung large cell carcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT01055314 Jan 2010 → Jun 2016 alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma National Cancer Institute (NCI) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00906373 Comparator May 2009 → Oct 2012 hepatocellular carcinoma Eli Lilly and Company Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 45 sources stand behind the page.

FieldValueCited text
Known as cixutumumab Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.” PMID 24439931 Jan 2014
29

“IMC-A12 (cixutumumab)” NCT00728949

NCT01263782

NCT00778167

NCT00699491

NCT00684983

NCT00880282

NCT00617708

NCT00781911

NCT01008566

NCT01120236

NCT00678769

NCT01142388

NCT00955305

NCT00639509

NCT01055314

NCT00870870

NCT00887159

NCT01614795

NCT01413191

NCT01016015

NCT01061749

NCT01007032

NCT01232452

NCT00831844

NCT01026623

NCT00986674

NCT01204476

NCT00609141

NCT00720174

Known as A12 “treated weekly with intravenous A12 (cixutumumab) and temsirolimus” NCT01016015
Known as IMC-A12 IMC-A12 (cixutumumab)” NCT00870870
15

NCT00769795

NCT00906373

NCT00845039

NCT00728949

NCT00668148

NCT00785941

NCT01160458

NCT00683475

NCT00957853

NCT00785538

NCT00778817

NCT01182883

NCT00617734

NCT00520481

NCT00503685

Known as NSC 742460 “Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas” NCT01016015
Action Inhibit “This binding action has been shown to inhibit the growth of a variety of human tumor cell lines.” NCT00617734
Modality Monoclonal antibody “IMC-A12 is a monoclonal antibody which binds to special receptors known as insulin-like growth factor-I receptor (IGF-IR).” NCT00617734
Route Intravenous “10 mg/kg i.v. infusion over 1 hour” NCT00520481
Target IGF1R “Anti-IGF-1R antibody cixutumumab” PMID 25858498 Apr 2015